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REVIEW
Abstract: Secondary hyperparathyroidism (SHPT) is commonly seen in patients with chronic
kidney disease (CKD). Even in early CKD, parathyroid hormone (PTH) levels are elevated,
maintaining mineral homeostasis at the cost of long-term bone health. One potent stimulus
for PTH secretion is a deficiency of active vitamin D. Replacement with calcitriol, the active
form of vitamin D, lowers PTH but often raises calcium and phosphorus levels, predisposing
patients to an increased risk of ectopic calcifications. Paricalcitol is a vitamin D analog designed
to treat SHPT without raising serum calcium and phosphorus levels. The intravenous
preparation of paricalcitol is used routinely in the hemodialysis population and has
demonstrated a survival benefit over calcitriol in hemodialysis patients. A new oral preparation
has now been developed for use in the pre-dialysis CKD population. Thus far, oral paricalcitol
has been shown to reduce PTH by an average of 42% in CKD patients, while having minimal
effects on serum calcium and phosphorus. While long term effects of the oral preparation
have yet to be studied, emerging evidence suggests that paricalcitol mediates a variety of
beneficial effects through the activation of vitamin D receptors which may result in improved
survival.
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Introduction
Secondary hyperparathyroidism (SHPT) is a serious complication of chronic kidney
disease (CKD). While overt manifestations such as pain, weakness, pruritis, and
metastatic calcifications may not occur until late in CKD or at end stage renal disease,
the disease process begins early in the course of CKD, at glomerular filtration rates
of about 60 ml/min/1.73 m
2 (Pitts et al 1988; Reichel et al 1991). Approximately 7
million Americans have kidney function at or below this level. Declining kidney
function leads to a deficiency in active vitamin D, or calcitriol, which plays a critical
role in the pathogenesis of SHPT and its associated cardiovascular complications.
However, treatment with calcitriol is limited by its hypercalcemic and
hyperphosphatemic effects. These side effects promote ectopic, and especially
vascular, calcifications which increase cardiovascular risk (Qunibi et al 2002;
Goodman et al 2003; Goldsmith et al 2004). Vitamin D analogs, like paricalcitol,
have been developed to suppress parathyroid hormone (PTH) secretion without
concomitant elevations in the serum calcium or phosphorus levels. This article will
review the pathophysiology of SHPT, the data on paricalcitol for the treatment of
SHPT, and the potential long term benefits of early oral administration of this
medication.
Calcitriol deficiency in SHPT
Calcitriol deficiency plays a central role in the pathogenesis of SHPT. The decline in
functional renal mass leads to a decrease in the 1-alpha hydroxylation of vitamin D
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to its active form, calcitriol. Under normal conditions,
calcitriol regulates the expression of PTH by suppressing
transcription of pre-pro-PTH messenger RNA (Russell et
al 1986; Silver et al 1986). Thus decreases in calcitriol levels
result in decreased activation of vitamin D receptors, leading
to increased expression of PTH and hyperplastic growth of
the parathyroid gland. Furthermore, calcitriol deficiency
results in decreased intestinal absorption of calcium. In
response to the fall in serum calcium levels, PTH secretion
increases as a compensatory mechanism to maintain mineral
homeostasis.
Calcitriol deficiency also decreases the activation of
other vitamin D receptors distributed throughout the body,
including the intestines, kidneys, bone, immune cells, skin,
heart, and brain (Mee et al 1996; Dusso and Brown 1998),
leading to a variety of adverse effects associated with SHPT.
At normal levels, calcitriol has a protective effect against
vascular calcifications. Activation of the vitamin D receptor
(VDR) on vascular smooth muscle cells has been found to
regulate the synthesis of type 1 collagen, core binding factor
alpha and bone morphogenic protein 2 – all of which
contribute to the development of arterial calcification and
mineralization (Virdi et al 1998; Bellows et al 1999; Drissi
et al 2002). Calcitriol may play an important role in
preventing atherosclerosis as well. Activation of the VDR
stimulates the protective effects of type 2 helper T (Th2)
cells through the induction of cytokines such as IL4 and
IL10 (Boonstra et al 2001; Barrat et al 2002). In addition,
calcitriol decreases interferon (IFN) gamma, which is an
important component of macrophage recruitment in the
pathogenesis of atherosclerotic lesions (Staeva-Vieira and
Freedman 2002). Calcitriol deficiency in renal failure
decreases VDR activation and may thus play a direct role
in mediating cardiovascular complications.
Treatment
The treatment of SHPT early in CKD involves some form
of active vitamin D along with dietary phosphorus restriction
and phosphorus-binding agents. Active vitamin D
supplementation with calcitriol has been shown to reduce
serum PTH levels and bone turnover in both animal studies
and in clinical trials (Slatopolsky et al 1984). However, the
administration of calcitriol also stimulates VDRs that
increase intestinal absorption of calcium and phosphorus
and suppress normal bone turnover, leading to elevations
in the calcium and phosphorus levels. Hypercalcemia and
hyperphosphatemia are associated with ectopic
calcifications and an increase in cardiovascular-related
deaths in dialysis patients (Qunibi et al 2002; Goodman et
al 2003; Goldsmith et al 2004). The process of vascular
calcification appears to begin in CKD as evidenced by the
data from the Dallas Heart Study and a recent study by Sigris
and colleagues (Kramer et al 2005; Sigris et al 2006).
Furthermore, the increasing calcium burden places the
patient in chronic positive calcium balance. Therefore, while
the administration of calcitriol is certainly effective,
elevations in serum calcium and phosphorus need to be
monitored regularly and the dose of calcitriol may be limited
by increases in these divalent ions.
Analogs of active vitamin D were developed to inhibit
parathyroid secretion while minimizing the effects of
vitamin D receptor activation elsewhere. Paricalcitol, 19-
nor-1,25(OH)2D2, is the most commonly used of these active
vitamin D analogs. It achieves its site selectivity via removal
of a methylene group from the carbon at the 19 position,
and a D2 side chain. While intravenous paricalcitol has been
used in dialysis patients since its approval in 1998, the oral
formulation has only recently been approved. Thus the
majority of studies evaluating the effectiveness of
paricalcitol, especially in comparison with other
formulations of active vitamin D, have been done with the
intravenous form in patients with end-stage renal disease
on dialysis. Like calcitriol, paricalcitol suppresses pre-pro-
PTH mRNA synthesis and has a prolonged effect of PTH
inhibition beyond its mean half-life of approximately 14
hours in hemodialysis patients (Cato et al 1998; Brandi et
al 2002; Staniforth et al 2005). However, in comparison
with calcitriol, paricalcitol has a decreased effect in intestinal
calcium absorption and bone mobilization (Coyne et al
2002). Animal studies in uremic rats found that paricalcitol
maintained effective PTH suppression, but had decreased
expression of markers for intestinal calcium transport
(Brown et al 2002).
Clinical trials have found similar results (Martin et al
1998b; Llach and Yudd 2001; Martin 2001; Sprague 2001).
In randomized, double-blind, placebo-controlled clinical
trials, paricalcitol decreased PTH by 60% without significant
change in calcium levels (Martin et al 1998a). Direct
comparisons of paricalcitol and calcitriol in the hemodialysis
population have shown that paricalcitol achieves equivalent
PTH suppression at a paricalcitol to calcitriol ratio of
approximately 3:1 (Martin et al 1998b; Llach and Yudd
2001). Furthermore, paricalcitol had a lower calcium-
phosphorus product than calcitriol even at doses 6–8-fold
higher than calcitriol (Coyne et al 2002). Paricalcitol is also
associated with a lower mortality (Teng et al 2003) in aTherapeutics and Clinical Risk Management 2006:2(3) 299
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historical cohort study, and lower hospitalization rate
(Dobrez et al 2004) in retrospective analyses, a benefit that
appeared to be independent of calcium, phosphorus, and
PTH levels in comparison with calcitriol.
Oral paricalcitol
The data with intravenous paricalcitol suggest that this
vitamin D analog is beneficial in controlling SHPT in the
dialysis population, maintaining a safer effect on calcium
and phosphorus levels while associated with improvement
in morbidity and mortality when compared with calcitriol.
However, the administration of the intravenous formulation
is not convenient in patients without the regular intravenous
access provided with hemodialysis, such as those on
peritoneal dialysis and patients with CKD not yet on dialysis.
Paricalcitol capsules were thus developed and recently
approved by the US Food and Drug Administration (FDA)
in May 2005 for use in the CKD population.
The oral formulation has the same structural
modifications and mechanism of action as the intravenous
form. It is metabolized by both hepatic and nonhepatic
enzymes (including CYP24), and it is eliminated primarily
through the hepatobiliary route. It can be dosed daily at a
starting dose of 1mcg in individuals with PTH <500 pg/mL
and 2 mcg in individuals with PTH >500 pg/mL. Thrice
weekly dosing is also highly effective. It is well absorbed
and reaches a peak concentration approximately 3 hours
after ingestion. Oral paricalcitol is generally well tolerated.
Its main side effects are related to gastrointestinal
discomfort. In a recent placebo controlled study, 6% of
patients on paricalcitol experienced nausea (vs 4% with
placebo) and 6% experienced vomiting (vs 4% with placebo)
(Coyne et al 2006).
Randomized trials have been conducted showing that
paricalcitol capsules demonstrate effective suppression of
PTH, achieving ≥30% reduction in PTH on 2 consecutive
measurements more frequently than those treated with
placebo (91% vs 13%, p<0.001) (Coyne et al 2006).
Furthermore there was no significant difference between
oral paricalcitol and placebo in the incidence of
hypercalcemia (>10.5 mg/dL) (2% vs 0% respectively,
p=0.237), hyperphosphatemia (>5.5 mg/dL) (10% vs 12%
respectively, p=0.830) or elevated calcium-phosphorus
products (>55 mg
2/dL
2) (12% vs 6% respectively, p=0.161).
Thus far there are no studies comparing oral paricalcitol
with other oral active vitamin D preparations in the pre-
dialysis CKD population. In placebo-controlled studies,
calcitriol (Slatopolsky et al 1984) and the three currently
available vitamin D analogs, alfacalcidol (Hamdy et al
1995), doxercalciferol (Coburn et al 2004), and paricalcitol
(Coyne et al 2006), all suppress PTH levels. A study in CKD
patients showed that oral calcitriol suppressed baseline PTH
levels by 25% over 1 year of treatment, but at doses between
0.25 mcg/day and 1 mcg/day, calcitriol led to hypercalcemia
in 64% of patients in the trial and a 139% increase in urinary
calcium excretion after 1 year (Calcitriol new drug
application [NDA] 18-044 FDA). Additional studies have
shown that while low doses of calcitriol are generally well
tolerated in the CKD population, the risk of hypercalcemia
increases when calcitriol dose exceeds 0.5 mcg/day (Nordal
and Dahl 1988; Baker et al 1989). The vitamin D analogs
alfacalcidol (1-alpha D3) and doxercalciferol (1-alpha D2)
have also demonstrated significant PTH suppression (28%
and 46% respectively) though hypercalcemia occurred in
15% of patients treated with alfacalcidol and 4% of those
on doxercalciferol (Hamdy et al 1995; Coburn et al 2004).
Urinary calcium concentrations increased by 41% and 42%
respectively, reflecting increased calcium load. In
comparison, paricalcitol capsules had a mean PTH
suppression of 42% with only 2% of patients in the
paricalcitol groups experiencing hypercalcemia (Coyne et
al 2006). Mean urinary calcium increased by 6% and mean
serum calcium increased about 1%. Indirect comparison of
these results suggests paricalcitol effectively suppressed
PTH with smaller alterations in serum calcium and
phosphorus.
Potential long term benefits
It is known that persistent PTH stimulation results in nodular
hyperplasia which may not regress even in the face of
normalized renal function (ie, after renal transplantation)
(McCarron et al 1982). Prolonged exposure to elevated PTH
levels may lead to irreversible parathyroid hyperplasia or
significant bone disease by the time patients reach end stage
renal disease (ESRD). Based on the evidence presented
above, oral paricalcitol is able to effectively control PTH
secretion in CKD patients when compared with placebo.
Early treatment with oral paricalcitol can thus attenuate the
development of SHPT and prevent progression to severe
forms of disease in the parathyroid gland and bone.
Paricalcitol has also been associated with benefits in
patient survival, hospitalizations, and mortality rates in
dialysis patients across all levels of serum calcium,
phosphorus, or PTH, suggesting that this benefit is not solely
attributable to vitamin D’s traditional role in bone and
mineral homeostasis (Teng et al 2003, 2005; Dobrez et alTherapeutics and Clinical Risk Management 2006:2(3) 300
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2004). Patients treated with paricalcitol had a 16% lower
mortality rate than those treated with calcitriol in a
historical cohort study of over 67 000 hemodialysis
patients
 (Teng et al 2003). This survival advantage was
also seen in patients who switched from calcitriol to
paricalcitol when compared with those who switched
from paricalcitol to calcitriol. A separate study found that
patients treated with paricalcitol also had decreased
hospitalizations and fewer hospital days per year than
those treated with calcitriol (Dobrez et al 2004).
The activation of vitamin D receptors by paricalcitol may
mediate a number of benefits independent of its effects on
mineral metabolism. Vitamin D receptors are dispersed
throughout the body in a number of tissues, and activation
of these receptors may affect not only secretion of PTH but
also modulation of the renin–angiotensin system, left
ventricular hypertrophy, and vascular calcification (Levin
and Li 2005). Activation of VDRs may have a role in
preserving renal function as well. In animal models, the
administration of calcitriol attenuated the development of
renal fibrosis in mice models through suppressing
transforming growth factor β (TGFβ) and inducing
hepatocyte growth factor (Li et al 2005), an important
cytokine that attenuates interstitial fibrosis by inhibiting
myofibroblast activation (Yang and Liu 2002). Preliminary
studies with paricalcitol show that intravenous paricalcitol
decreases renal interstitial fibrosis in mouse models of
obstructive nephropathy (Tan and Liu 2005), and oral
paricalcitol has demonstrated a protective effect on residual
renal function in the CKD population by reducing
proteinuria independent of the use of renin–angiotensin
blocking agents (Agarwal et al 2005). Further clinical trials
are needed to investigate the additional benefits of oral
paricalcitol in CKD patients and whether it impacts
morbidity, mortality, and time to dialysis.
Pharmacoeconomics
The cost of care for the management of SHPT is significant.
Short term costs include the cost of medications, routine
blood work to monitor calcium and phosphorus, and the
management of adverse effects. Despite its higher cost,
paricalcitol has a lower incidence of hypercalcemia, which
may translate into fewer adverse effects and a decreased
need for frequent checks of calcium and phosphorus levels.
Long term costs include cost of care for hospitalizations
and treatment of significant bone disease and cardiovascular
events associated with untreated SHPT. Early administration
of oral paricalcitol may provide effective control of SHPT
without necessitating dose reductions for hypercalcemia or
hyperphosphatemia, thus preventing the progression of bone
disease and parathyroid hyperplasia in SHPT, leading to
fewer hospitalizations. The effect of paricalcitol on
preservation of renal function would also reduce the cost of
care substantially. Paricalcitol may increase the time to
dialysis in CKD patients, thus generating substantial savings.
Additionally, the cost of management of SHPT among
dialysis patients is likely to be dramatically less if
parathyroid hyperplasia is reduced during the CKD period.
Conclusion
Treatment of SHPT continues to be an important part of
care in the patient with CKD. Paricalcitol is a well
tolerated and effective medication for reducing PTH
levels in the CKD population while minimizing
hypercalcemia and hyperphosphatemia. Paricalcitol
capsules permit early intervention to halt SHPT and
reverse bone-related disease, especially in those patients
who are unable to take calcitriol due to hypercalcemia
and hyperphosphatemia. However, the benefits of
paricalcitol likely extend beyond its effects on renal
mineral metabolism. Clinical trials with intravenous
paricalcitol show a survival advantage and a decrease in
hospitalizations when compared to calcitriol, while
animal studies suggest that paricalcitol attenuates
vascular calcification, atherosclerosis, and renal fibrosis.
This may translate into substantial decreases in the cost
of care of patients with kidney disease and SHPT. Further
studies will be needed to examine the role of this vitamin
D analog in preventing vascular calcification, preserving
renal function, and limiting left ventricular hypertrophy.
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